Academic literature on the topic 'A P M Forests Pty Ltd'

Recent drilling by BHP Billiton Pty Ltd in WA-155-P(1) and WA-12-R, on behalf of its partners Apache Energy Ltd and INPEX ALPHA LTD, has resulted in the discovery of four oil fields in the southern Exmouth Sub-basin, namely Ravensworth, Crosby, Stickle and Harrison. These discoveries, together with the earlier discoveries made by West Muiron–5 and Pyrenees–2, define the Early Cretaceous Pyrenees Member play fairway.The Pyrenees Trend play was first conceived in 1999 following appraisal of the Macedon gas field (Keall, 1999), but the concept remained dormant until the integration of geological information with high quality 3D seismic data led to the recognition of hydrocarbon related seismic attributes in the postulated play fairway.Ravensworth–1 intersected a 37 m gross oil column below a 7 m gas cap in high quality Pyrenees Member sandstones beneath the regionally significant Intra- Hauterivian Unconformity. Ravensworth, located on a northeast–southwest trending fault terrace, is a complex structural-stratigraphic trap that relies on separate top, base and cross-fault seals. High quality 3D seismic data coupled with recent interpretation techniques were integral to its discovery. In particular, the quantitative interpretation of seismic amplitude populations was a key factor in decreasing exploration risk.The Ravensworth discovery was followed by successful exploration wells on the adjacent Crosby, Stickle and Harrison fault terraces. Four appraisal wells have since been drilled at the northern ends of the main discoveries.The oil in the Pyrenees Member discoveries is biodegraded, moderately viscous (8–11 cp) and heavy (18–19° API gravity). Methane-dominated gas caps were intersected in Ravensworth–1, West Muiron–5 and Pyrenees–2.The recent drilling and coring campaigns by BHP Billiton and others in the Exmouth Sub-basin have significantly advanced knowledge of the stratigraphy and depositional environments of the late Tithonian to early Berriasian Macedon, Muiron and Pyrenees Members of the lower Barrow Group. The lower Barrow Group is a third order sequence deposited rapidly in marine to fluviodeltaic environments in response to the breakup of Gondwana and the onset of active rifting along the West Australian margin.BHP Billiton and its joint venture partners are assessing the commercial viability of the Pyrenees Trend discoveries.

Background: Literature suggests an association between shift work and cardiovascular disease (CVD). Limited evidence is available on how a cessation of shift work affects CVD risk factors. Aim: We investigated whether a five-month plant shutdown affected CVD risk factors in 30 industrial shift workers. Methods: We collected demographic data, self-reported data on physical activity (PA) and medical history by questionnaire. Pre- and post-plant shutdown, we measured blood pressure (BP), heart rate, lipids, glycosylated hemoglobin (HbA1c) and C-reactive protein (CRP). Additionally, we collected markers of inflammation, Matrix metalloproteinase-9 (MMP-9), Interleukin-6 (IL-6), Monocyte chemoattractant protein-1 (MCP-1), Tumor necrosis factor-alpha (TNF-α), P-selectin, Interleukin-1 beta (IL-1β), and Interleukin-23 (IL-23). We also examined arterial stiffness (central blood pressure, augmentation pressure, and pulse wave velocity) by means of SphygmoCor® (AtCor Medical Pty Ltd., Sydney, Australia). We monitored sleep by actigraphy prior to and after plant shutdown, with additional registration of sleep quality and assessment of insomnia symptoms. Results: After five months of plant shutdown, we found that HbA1c increased by 1.9 mmol/mol, weight by 1 kg and MCP-1 by 27.3 pg/mL, all unexpectedly. The other markers of inflammation did not change during shutdown, but CRP decreased close to significant levels. There were no changes in lipids during follow-up. Pulse-wave velocity (PWV) was reduced from 8.1 m/s (SD = 1.5) to 7.6 m/s (SD = 1.5), p = 0.03. The workers reported fewer signs of insomnia after shutdown. Conclusions: Our findings suggest that a five-month cessation in shift work increases weight and HbA1c, but also improves insomnia symptoms and reverses arterial stiffening.

Abstract Aim: To perform a systematic review of the efficacy of monotherapy with bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma. Methods: Published English literature from 1966 to June 2005 (MEDLINE, EMBASE, Cochrane library), publication reference lists, Janssen-Cilag Pty Ltd data-on-file, and abstracts from recent multiple myeloma conferences were reviewed. Prospective studies containing at least a single arm of any treatment group with n ≥ 30 and using continuing or variable thalidomide dosing were included. Studies adding dexamethasone for non-responders were excluded. Outcomes were analysed on an intent-to-treat basis. Statistical pooling was performed where possible for the following outcome measures: primary outcome of response rate, defined by a serum M-protein reduction ≥50% (A) and strict (e.g. EBMT) criteria (B), and for the secondary outcomes of overall survival and progression-free survival. Results: One bortezomib (n=333, APEX, NEJM2005, 352; 2487–98) and 15 thalidomide (n=1007) studies were included. Patient baseline characteristics including age, gender, IgG:IgA, disease duration and β2M were well matched, except that 48% of bortezomib patients had received prior thalidomide. On an intent-to-treat basis, the overall estimate for response rate (A) was 53% for patients receiving bortezomib versus 32% for thalidomide (p<0.001, n=10 studies). For response rate (B) the estimate was 36% for patients receiving bortezomib versus 22% for thalidomide (p<0.001, n=4 studies). One-year survival was 81% for patients receiving bortezomib versus 67% for thalidomide (p<0.001, n=6 studies). Due to differences in disease monitoring and definitions of progression, it was not possible to compare results for progression-free survival. Conclusion: In patients with relapsed or refractory multiple myeloma, bortezomib achieved significantly higher response rates and longer one-year survival than thalidomide, despite 48% of bortezomib-treated patients having received prior thalidomide.

At the present time the great part of soils is exposed to various negative processes. One of the basic processes that lead to the degradation of soils in Ukraine is the erosion. According to the recent data, water and wind erosion covers 13.9 million hectares; it is about 33 % of the total arable land in the country. On this basis, the greater relevance belongs to the scientific studies displaying the features of negative phenomena of our soil, and, most importantly, the ways of solving of these urgent problems on the soil cover of Ukraine. The monograph «Soil erosion in Ukraine: the evolution of theory and practice» of such famous scientists in the field of Soil Erosion Science as Voloshchuk M. D., Petrenko N. I. and Yatsenko S. V. is one of such fundamental works. In the present monograph, considerable attention is paid to the periodization of the formation and development of the doctrine of soil erosion in Ukraine. The authors identify six basic stages of formation of the national Soil Erosion Science. The paper discusses the characteristic features of isolation of Soil Erosion Science as an independent scientific direction and a self-discipline, which are based on the works of such renowned scientists as P. S. Tregubov, M. N. Zaslavsky and G. I. Shvebs. A significant place in the monograph is devoted to the characteristics of the scientific centers of Ukraine, in which the Soil Erosion Science has been developed. These centers are distinguished by leading scientists, under the leadership of whom, the erosion processes have been studied. The authors of the monograph provides four main scientific centers of the country in the field of Soil Erosion Science development: National Scientific Centre «Institute of Agriculture of the National Academy of Agricultural Sciences» (central region), National Scientific Center «Institute for Soil Science and Agrochemistry Research named after O. N. Sokolovsky», Scientific-Technical Center «Fertility» (Kharkiv region), Odessa I. I. Mechnikov National University (south region), Lviv National Agrarian University, Institute of Ecology of the Carpathians of National Academy of Sciences of Ukraine, Ivan Franko National University of Lviv and others (west region). In addition to considering the features of the listed centers, in the work there is a presentation of a brief description of the project, research institutes, agricultural and agroforestry research stations that are active in a scientific work in relation to soil erosion processes. In the work, there are also the historical aspects and mechanisms for the further development of wind erosion researches. Considerable attention the authors of the monograph pay to the analysis of the current state, challenges and prospects of solving the problem on protecting the soil from erosion. The main problem of the country's soil, which is the cause of widespread erosion, is a very high agricultural development of the territory, more than half of which falls onto an arable land. At the end of the monograph, there are a large number of photos, provided by Professor M. D. Voloshchuk, which recorded various aspects of soil erosion manifestations, as well as the ways of its overcoming in the conditions of forest-steppe and steppe zones in Ukraine and on the territory of Moldova. The reviewed monograph is certainly a very relevant and timely generalizing scientific research that will be useful in the theoretical and practical use of students, academic staff of the natural and agricultural higher education institutions, research organizations.

The basidiomycete Heterobasidion annosum (Fr.) Bref. (=Fomes annosus (Fr.) Cooke), one of the most important pathogens in coniferous forests in Europe, Asia, and North America, causes root and butt rot. H. annosum was first recorded on Pinus pinaster Ait. (commonly known as Maritime pine) in France and Great Britain in 1961 (4) and Portugal in 1986 (2). P. pinaster is the most widespread conifer in Spain, with more than 700,000 and 600,000 ha in pure and mixed stands, respectively. Over the last few years, P. pinaster decline was observed in several stands in the center of the Iberian Peninsula. Unusual crown transparency, small needles, foliage discoloration, and early tree death are characteristic decline symptoms associated with the high mortality rate on this species. In June of 2010, 11 trees (40 to 60 years old) with a different degree of decline were felled in two zones (42°2′41″N, 3°18′14″W, elevation 1,096 m and 41°55′40″N, 3°12′3″W, elevation 1,128 m) and cut into sections (stump height, breast height, and near the top). Wood slices were removed from each section and taken to the laboratory. Samples were placed in moist chambers with optimal conditions of humidity and temperature to enhance pathogen growth. After 20 days of incubation in darkness at 25°C, H. annosum (anamorph Spiniger meineckellum [A. Olson] Stalpers) occurred on most of these slices. Conidiophores with subglobose to pyriform conidia (5.8 × 4.2 μm) were observed with a compound microscope. The fungus was isolated to extract DNA by disruption of the mycelium followed by washes with phenol/chloroform/isoamyl alcohol solution (25:24:1). DNA was precipitated with 20% polyethylene glycol solution. PCR was carried out according to the instructions of the manufacturer of Dynazyme II DNA polymerase (Finnzymes Ltd, Espoo, Finland) with ITS primers, 1F (5′-CTTGGTCATTTAGAGGAAGTAA-3′) and 4 (5′-TCCTCCGCTTATTGATATGC-3′). After DNA purification, samples were sequenced (SECUGEN, Madrid, Spain) and aligned and corrected with Geneious Pro 5.3 to obtain the consensus sequences. Resulting DNA sequences of two isolates were deposited in GenBank (Nos. FR850494 and FR850495), and compared with a Blastn search at GenBank showing 100% identity and 100% coverage with H. annosum sensu stricto, former ISG-P (intersterility group of pines). For pathogenicity tests, 10 seedlings (2 year old) were inoculated with autoclaved P. pinaster wood chips colonized by H. annosum, and 10 control seedlings were inoculated with noncolonized wood chips. Inoculums were prepared by growing H. annosum on 4-mm-diameter wood chips placed on potato dextrose agar media for 3 weeks. The wood chips were put inside an oblique incision made at 6 cm above the soil line and wrapped with Parafilm. After 8 weeks in a growth chamber at 22.5°C with a 14-h photoperiod, the inoculated seedlings showed typical symptoms and 3 seedlings of 10 were dead. H. annosum was previously recorded on P. sylvestris in central Spain (1), causing needle drop, swelling at the stump height, and presence of dead trees by circular areas. This pathogen was also reported on P. nigra in northeastern Spain, associated with defoliation and mortality (3). To our knowledge, this is the first record of H. annosum on P. pinaster in Spain. References: (1) J. Benito-Martínez. An. Jardín Bot. Madrid 3:23, 1943. (2) N. Neves et al. EPPO Bull. 16:505, 1986. (3) J. Oliva et al. Bol. Sanidad Vegetal. Plagas. 34:415, 2008. (4) P. Spaulding. US Dep. Agric. Agric. Handb. 197:100, 1961.

In 2003 and 2004, a survey of grapevine (Vitis vinifera L.) trunk pathogens was conducted in 30 vineyards in the Western and Northern Cape and Limpopo provinces of South Africa. In each vineyard, 20 visually healthy plants were sampled randomly by removing the distal part of one cordon arm. Isolations were made onto potato dextrose agar (PDA) from the internal wood decay symptoms observed in the cordon samples. Seven Botryosphaeriaceae spp. were identified, including Lasiodiplodia crassispora (1). Other Botryosphaeriaceae spp. are known grapevine trunk pathogens (2). Species identity was confirmed by DNA sequence data of the partial translation factor 1-α gene (1) and sequences deposited in GenBank (GU233658 and GU233659). The L. crassispora isolates (CBS 125626 and 125627) were associated with brown internal necrosis, a known symptom of grapevine Botryosphaeriaceae spp. infection (3), in the cordon arms of Ruby Cabernet grapevines occurring in two vineyards in the Northern Cape Province. L. crassispora was described from cankered wood of Santalum album in Western Australia and endophytically from Eucalyptus urophylla in Venezuela (1). Its grapevine pathogen status was determined using both isolates in a repeated pathogenicity test that included three isolates each of Botryosphaeria dothidea and Neofusicoccum australe as positive controls (2), Trichoderma harzianum as a nonpathogen treatment, and an uncolonized agar plug as a negative control. The Botryosphaeriaceae spp. and T. harzianum were plated on PDA and incubated at 25°C for 7 days. Lignified, 6-month-old shoots of grapevine cv. Chardonnay were excised from grapevines with internodes 4 to 6 used for inoculations. Before wounding, shoots were disinfected by submersion for 1 min in a 1 ml/liter solution of a quaternary ammonium compound (Sporekill; ICA International Chemicals (Pty) Ltd, Stellenbosch, South Africa). Twelve shoots were used for each isolate or control treatment. Wounds were made 2 mm deep on the fifth internode of the shoots with a 5-mm flame-sterilized cork borer (2,3). Wounds were inoculated with a pathogen colonized agar plug (5 mm in diameter) or an uncolonized agar plug and then covered with Parafilm (2,3). Inoculated shoots were incubated in the dark in moist chambers for 14 days at 25°C. After incubation, the bark of the shoots was peeled from the area around the wound and the lengths of any resultant lesions were measured under sterile conditions. The inoculum effect was assessed by analysis of variance and Student's t-test. Results showed that significantly (P < 0.0001) longer lesions were caused by L. crassispora (13.36 mm) compared with N. australe (9.27 mm) and B. dothidea (5.28 mm) and also significantly longer than lesions caused by the nonpathogen and negative controls (3.23 and 2.90 mm, respectively). To determine if lesions were caused by inoculated fungi, isolations were made from the tissue at the edges of the lesions by aseptically removing five 0.5 × 1 mm pieces of wood and placing them on PDA dishes amended with 0.04 g/liter of streptomycin sulfate. Dishes were incubated under normal fluorescent light at 25°C for 14 days before identifying isolated fungi based on morphological and cultural characteristics (1). To our knowledge, this is the first report of L. crassispora as a grapevine pathogen. References: (1) T. I. Burgess et al. Mycologia 98:423, 2006. (2) J. M. van Niekerk et al. Mycologia 96:781, 2004. (4) J. M. van Niekerk et al. Phytopathol. Mediterr. 45:S43, 2006.

Background: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) are &gt;70 years old and have poor clinical outcomes attributable to treatment-related factors or to disease biology. Genotyping data in elderly DLBCL patients is limited because of lack of representation in clinical trials. R-mini-CHOP is better tolerated than R-CHOP in elderly DLBCL but with reduced efficacy. The addition of ibrutinib to R-CHOP has been shown to be effective in younger pts aged &lt; 60 years but is associated with poor tolerability and outcomes in older patients. The ALLG Ibrutinib with R-mini-CHOP (IRiC) study, a prospective multicentre single-arm phase II study in elderly (≥ 75 years) DLBCL patients provided an opportunity to genotype this uncommon cohort. We therefore aimed to map the genetic landscape of mutations in elderly DLBCL and compare them to a non-trial younger cohort. Methods: Mutations in genes commonly associated with DLBCL were assessed in 55 IRIC study patients with a median age of 81 years (75-91 years) and a gender ratio of 1.0 (27 M/28 F). A cohort of 51 non-trial patients withde novoDLBCL treated with anthracycline-based regimens was also genotyped. The median age of the control group was 65 years (29-91 years) with a gender ratio of 1.2:1 (28 M/23 F). The cell of origin (COO) measured using gene expression profiling on 39/55 trial patients (non-GC=13, GC= 22, unclassified= 4), and Hans algorithm on 45/51 non-trial patients (non-GC=14, GC=31) was comparable (p=0.571). Outcome data was available at a median follow-up of 18 and 40 months for the trial and non-trial cohorts respectively. We extracted genomic DNA from and performed next generation sequencing on diagnostic formalin-fixed paraffin-embedded or fresh frozen tissue samples using a customized capture library (SureSelectXT Target Enrichment System, Aqilent Technologies) covering genes involved in lymphomagenesis. The purified libraries were sequenced on the Illumina NextSeq500 platform at AGRF (Australian Genome Research Facility, Australia). Mutations in the following genes were compared across the two cohorts: ARID1A, BCL2, BTG1, BTG2, CARD11, CCND3, DTX1, EP300, ETS1, EZH2, FOXO1, GNA13, HIST1H1C, IKBKB, IRF8, KDM2B, KLHL6, MYC, MYD88, NOTCH1, NOTCH2, PIK3CD, PIM1, PRDM1, PTEN, PTPN21, SGK1, SPEN, STAT3, TET2, TNFAIP3, TNFRSF11A, TNFRSF14, TP53 and TRAF5. Statistical analysis for nominal data was done using the chi-square test and for ordinal data using the Kruskal-Wallis test (p &lt; 0.05= significant). Kaplan-Meier curves were calculated for patients with and without each mutation and the curves compared using a log-rank approach. Results: Patients were divided into 2 groups, IRiC trial cohort aged &gt;75 years (n=55) + non-trial elderly patients &gt;75 years (n=9) =elderly cohort(n=64) and non-trialnon-elderly cohortof patients &lt; 75 years (n=42). As expected, elderly patients were more likely to have high-risk disease with higher IPI of ≥ 3 (n=42, n=17, p=0.009). There was no significant difference in gender or COO. The frequency of mutations in the elderly (n=64) was compared to the non-elderly cohort (n=42). NOTCH2 was the most common mutation irrespective of age (34 [53%]; 16 [38%], p=0.129). Notably, we found that mutations in MYC (8 [12.5%]; 0, p= 0.021), PTEN (17 [26.5%]; 4 [9%], p=0.045) and TET2 (28 [43.7%]); 7 [16.6%], p=0.004) were more frequent in the elderly. As expected, MYD88 and CD79B mutations were more frequently associated with non-GC subtype (p=0.001). No other associations with COO were identified. No clear prognostic individual genes or gene clusters could be identified in the trial or the elderly cohort. Ibrutinib-responsive (MYD88 [L265P n=7] and CD79B [n=11]) and ibrutinib-resistant mutations (CARD11 [n=6] or PIM1 [n=12]) did not show clear associations with response rate, overall survival or progression-free survival. Conclusions: Our study found that the mutational profile of elderly DLBCL patients aged ≥ 75 years is enriched for targetable mutations in MYC, PTEN and TET2 compared to those &lt; 75 years. PTEN and TET2 are tumour suppressors and MYC is an oncogene with an important regulatory role in cell growth and proliferation. We hypothesize that hypo-methylating agents targeting TET2, BET inhibitors in MYC mutated tumours and PI3K inhibitors to target PTEN deficient lymphoma may help improve clinical outcomes in elderly DLBCL. No clear prognostic markers were identified in this small cohort. Disclosures Trotman: Celgene:Research Funding;BeiGene:Research Funding;Takeda:Research Funding;PCYC:Research Funding;F. Hoffmann-La Roche:Research Funding.Verner:Janssen Cilag Pty Ltd.:Research Funding.Gandhi:Celgene:Research Funding;Bristol-Myers Squibb:Research Funding;Mater Research:Current Employment;Janssen-Cilag:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding;Roche:Other: Travel, accommodation, expenses ;Genentech:Honoraria;Gilead Sciences:Honoraria;Amgen:Honoraria;Merck Sharp & Dohme:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.Gandhi:Integrated Sciences:Current Employment.Talaulikar:Takeda:Research Funding;Amgen:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding;Janssen:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau;Roche:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Abstract Introduction R-mini-CHOP is an established standard of care in elderly patients with DLBCL, with a 2yr OS of 59% and PFS of 47% (Peyrade et al, Lancet Oncol 2011). The addition of ibrutinib to full dose R-CHOP in younger pts with DLBCL has efficacy, but significant toxicity limits the ability to complete therapy in pts ≥60 yrs (Younes et al, JCO 2019). We previously demonstrated the deliverability of ibrutinib with R-mini-CHOP in 80 pts ≥75yrs with DLBCL with a median average relative total dose of 97%; 77% of pts received 6 cycles of R-mini-CHOP despite SAEs in 62% (Verner et al, Haematol Oncol 2019). Here we present the primary efficacy endpoint and key secondary and exploratory endpoints. Methods This was a prospective, multicenter, single-arm, phase 2 study of patients aged ≥75yrs with newly diagnosed DLBCL. Pts received six 21-day cycles of ibrutinib 560mg/d and R-mini-CHOP (Rituximab 375mg/m 2, cyclophosphamide 400mg/m 2, doxorubicin 25mg/m 2, vincristine 1mg on day 1 & prednisone 40mg/m 2 or 100mg/d x 5) followed by an additional two 21-day cycles of rituximab + ibrutinib (or high dose methotrexate for CNS prophylaxis). The efficacy primary endpoint was 2yr OS. Sample size calculations were made using a one-sample two-sided approach to detect a 15% improvement on the fixed reference OS (59%) and PFS (47%) rates (Peyrade et al, Lancet Oncol 2011). Results Eighty pts were recruited from Nov 2015 to Dec 2018. One died prior to receiving treatment and is not included in the analysis. Median age was 82yrs (75-95); 51% female, 81% stage III/IV and 63% IPI 3-5: 47% had a CIRS-G score of ≥6 (range 0-17). On centralized immunohistochemistry (IHC), 57% (45/79) were non-Germinal Centre B cell-like (GCB) subtype; 43% (34/79) were GCB. At a data cut-off of 6June 21, median follow-up was 29.5 months (m) (0.2 to 66.3). Two-year OS was 68% (95% CI 55-77%), not differing significantly from the null hypothesis of 59% (p=0.10), (Figure 1A). Median OS was not reached (NR) (95% CI 34m to NR), and was longer in those with lower IPI (IPI 1-3: NR, IPI 4: 35m, IPI 5: 19m). Two-year PFS was 60% (95% CI 47-70%), significantly different from the reference 47% (p&lt;0.03), (Figure 1B). Median PFS was NR (95% CI 20m to NR). Two-year DFS was 85% (95% CI 60-95%), median NR (95% CI 32m to NR). COO had no impact on either 2yr OS [median GCB NR (95% CI 29m to NR), median non-GCB NR (95% CI 24m to NR) p=0.99] or 2yr PFS [median GCB 39m (95% CI 17m to NR), median non-GCB NR (95% CI 19m to NR) p=0.97]. Cause of death in 28/79 pts (35%) was: 16 progressive lymphoma, 5 infection, 2 respiratory failure, 2 other malignancy, 1 cardiac arrest, 1 intra-abdominal hemorrhage, 1 gastric hemorrhage. At least one adverse event (AE) occurred in 99% pts (78/79): 30% (24/79) grade 1-2, 64% (49/79) grade 3-4, and 6% (5/79) grade 5. Most common grade ≥3 AEs were lung infection (13%), other infections (11%), anemia (11%), febrile neutropenia (9%), thrombocytopenia (9%), and atrial fibrillation (8%). Serious AEs occurred in 67%: most commonly lung infection (11%), atrial fibrillation (9%), fever (9%), and other infection (9%). 12/14 pts with atrial fibrillation/flutter were new onset. Ibrutinib was temporarily ceased in 62% of patients, and permanently ceased in 25%, mostly due to adverse events. As previously reported, the overall response rate on an intention to treat basis was 57/80 (71%) (Verner et al, ASH 2019). Response rates did not differ by cell of origin (COO) (ORR: non-GCB 76%, GCB 68% p=0.44). When recorded, pt's EORTC-QLQ-C30 global health status significantly improved between screening [n=78; mean (SD) 58(25)], end of treatment [n=57; 63(23)] and 18mo post-treatment [n=29; 74(19)] p=0.007. Significant reductions in fatigue, nausea and vomiting, pain, insomnia, appetite loss, constipation and diarrhea were also observed in respondents. There was no impact of CIRS-G score on disease response rate or risk of death. Conclusion The addition of ibrutinib to R-mini-CHOP was deliverable and improved 2-yr PFS compared to R-mini-CHOP alone. However, while there was a trend towards improvement in 2-yr OS, a target 15% increase was not achieved in this small sample size. Despite considerable and not unexpected toxicity in this elderly cohort, the QOL and functional improvements in survivors are also promising. These data support further study of the addition of ibrutinib to R-mini-CHOP in elderly patients with DLBCL. Figure 1 Figure 1. Disclosures Verner: Janssen-Cilag Pty Ltd: Research Funding. Hawkes: Merck KgA: Research Funding; Bristol Myers Squib/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Specialised Therapeutics: Consultancy; Antigene: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees; Regeneron: Speakers Bureau; Merck Sharpe Dohme: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel and accommodation expenses, Research Funding, Speakers Bureau; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Lee: Roche: Honoraria; BeiGene: Membership on an entity's Board of Directors or advisory committees. Cheah: BMS: Consultancy, Research Funding; Abbvie: Research Funding; Janssen: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Ascentage Pharma: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; TG therapeutics: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: travel, Research Funding. Purtill: Novartis: Honoraria; Gilead: Honoraria; BMS Celgene: Honoraria. Enjeti: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Speakers Bureau; AbbVie: Honoraria; Sanofi: Honoraria; Astra Zeneca: Honoraria. Curnow: Bayer: Consultancy, Research Funding; Pfizer/BMS: Consultancy, Honoraria; Mylan: Consultancy; Norgine: Consultancy, Honoraria. Butcher: WriteSource: Current Employment, Other: Medical writing for Pharma companies. Not pertinent to this abstract for which author is study Statisticiam. Trotman: JANSSEN: Research Funding; TAKEDA: Research Funding; BMS: Research Funding; PCYC: Research Funding; roche: Research Funding; beigene: Research Funding. OffLabel Disclosure: Ibrutinib is not approved for use in DLBCL

The study aims to assess the rate of erosion that occurred in Manjunto Watershed and financial loss using Geographic Information System and Remote Sensing. Model used to determine the erosion is E30 models. The basis for the development of this model is to integrate with the slope of the slope between NDVI. The value of NDVI obtained from satellite imagery. Slope factor obtained through the DEM processing. To determine the amount of economic losses caused by erosion used the shadow prices. The amount of nutrients lost converted to fertilizer price. The results showed that the eroded catchment area has increased significantly. The rate of average annual erosion in the watershed Manjunto in 2000 amounted to 3 Mg ha-1 yr-1. The average erosion rate in the watershed Manjunto annual increase to 27 Mg ha-1 yr-1 in the year 2009. Economic losses due to erosion in 2009 was Rp200,000,- for one hectare. Total losses due to erosion for the total watershed area is Rp15,918,213,133, -. The main factor causing the high rate of erosion is high rainfall, slope and how to grow crops that do not pay attention to the rules of conservation.Keywords: Soil erosion, digital elevation model, GIS, remote sensing, valuation erosion[How to Cite: Gunawan G, D Sutjiningsih, H Soeryantono and S Widjanarko. 2013.Soil Erosion Prediction Using GIS and Remote Sensing on Manjunto Watershed Bengkulu-Indonesia. J Trop Soils 18 (2): 141-148. Doi: 10.5400/jts.2013.18.2.141][Permalink/DOI: www.dx.doi.org/10.5400/jts.2013.18.2.141]REFERENCESAksoy E, G Ozsoy and MS Dirim. 2009. Soil mapping approach in GIS using Landsat satellite imagery and DEM data. Afr J Agric Res 4: 1295-1302.Ananda J and G Herath. 2003. Soil erosion in developing countries: a socio-economic appraisal. J Environ Manage 68: 343-353.Ananda J, G Herath and A Chisholm. 2001. Determination of yield and Erosion Damage Functions Using Subjectivly Elicited Data: application to Smallholder Tea in Sri Lanka. Aust J Agric Resour Ec 45: 275-289.Ande OT, Y Alaga and GA Oluwatosin. 2009. Soil erosion prediction using MMF model on highly dissected hilly terrain of Ekiti environs in southwestern Nigeria. Int J Phys Sci 4: 053-057.Arnold JG, BA Engel and R Srinivasan. 1998. A continuous time grid cell watershed model. Proc. of application of Advanced Technology for management of Natural Resources.Arsyad S. 2010. Konservasi Tanah dan Air. IPB Press. Bogor-Indonesia (in Indonesian).Asdak C.1995. Hydrology and Watershed Management. Gadjah Mada University Press, Yogyakarta.Barlin RD and ID Moore. 1994. Role of buffer strips in management of waterway pollution: a review. Environ Manage 18: 543-58.Brough PA.1986. Principle of Geographical Information Systems For Land Resources Assessment. Oxford University Press, 194p.Clark B and J Wallace. 2003. Global connections: Canadian and world issues. Toronto, Canada: Pearson Education Canada, Inc.Cochrane T A and DC Flanagan. 1999. Assessing water erosion in small watershed using WEPP with GIS and digital elevation models. J Soil Water Conserv 54: 678 685.Dames TWg. 1955. The Soils of East Central Java; with a Soil Map 1:250,000. Balai Besar Penjelidikan Pertanian, Bogor, Indonesia.Dixon JA, LF Scura, RA Carpenter and PB Sherman. 2004. Economic Analysis of Environmental Impacts 2nd ed. Eartscans Publication Ltd., London.Fistikoglu O and NB Harmancioglu. 2002. Integration of GIS with USLE in Assessment of Soil Erosion. Water Resour Manage 16: 447-467.Green K. 1992. Spatial imagery and GIS: integrated data for natural resource management. J Forest 90: 32-36.Hazarika MK and H Honda. 2001. Estimation of Soil Erosion Using Remote Sensing and GIS, Its Valuation & Economic Implications on Agricultural Productions. The 10th International Soil Conservation Organization Meeting at Purdue University and the USDA-ARS Soil Erosion Research Laboratory.Hazarika S, R Parkinson, R Bol, L Dixon, P Russell, S Donovan and D Allen. 2009. Effect of tillage system and straw management on organic matter dynamics. Agron Sustain Develop 29: 525-533. doi: 10.1051/agro/2009024. Honda KL, A Samarakoon, Y Ishibashi, Mabuchi and S Miyajima.1996. Remote Sensing and GIS technologies for denudation estimation in Siwalik watershed of Nepal,p. B21-B26. Proc. 17th Asian Conference on Remote Sensing, Colombo, Sri lanka.Kefi M and K Yoshino. 2010. Evaluation of The Economic Effects of Soil Erosion Risk on Agricultural Productivity Using Remote Sensing: Case of Watershed in Tunisia. International Archives of the Photogrammetry, Remote Sensing and Spatial Information Science, Volume XXXVIII, Part 8, Kyoto Japan.Kefi M, K Yoshino, K Zayani and H Isoda. 2009. Estimation of soil loss by using combination of Erosion Model and GIS: case of study watersheds in Tunisia. J Arid Land Stud 19: 287-290.Lal R. 1998. Soil erosion impact on agronomic productivity and environment quality: Critical Review. Plant Sci 17: 319-464.Lal. 2001. Soil Degradation by Erosion. Land Degrad Develop12: 519-539.Lanya I. 1996. Evaluasi Kualitas lahan dan Produktivitas Lahan Kering Terdegradasi di Daerah Transmigrasi WPP VII Rengat Kabupaten Indragiri Hulu, Riau. [Disertasi Doktor]. Program Pasca Sarjana IPB, Bogor (in Indonesian).Mermut AR and H Eswaran. 2001. Some major developments in soil science since the mid 1960s. Geoderma 100: 403-426.Mongkolsawat C, P Thurangoon and Sriwongsa.1994. Soil erosion mapping with USLE and GIS. Proc. Asian Conf. Rem. Sens., C-1-1 to C-1-6.Morgan RPC, Morgan DDV and Finney HJ. 1984. A predictive model for the assessment of erosion risk. J Agric Eng Res 30: 245-253.Morgan RPC. 2005. Soil Erosion and Conservation. 3rd ed. Malden, MA: Blackwell Publishing Co.Panuju DR, F Heidina, BH Trisasongko, B Tjahjono, A Kasno, AHA Syafril. 2009. Variasi nilai indeks vegetasi MODIS pada siklus pertumbuhan padi. J.Ilmiah Geomat. 15, 9-16 (in Indonesian).Pimentel D, C Harvey, P Resosudarmo, K. Sinclair, D Kurz, M Mc Nair, S Christ, L Shpritz, L Fitton, R Saffouri and R Balir. 1995. Environmental and Economic Costs of Soil Erosion and Conservation Benefits. Science 267: 1117-1123.Saha SK and LM Pande. 1993. Integrated approach towards soil erosion inventory for environmental conservation using satellite and agrometeorological data. Asia Pac Rem Sens J 5: 21-28.Saha SK, Kudrat M and Bhan SK.1991. Erosional soil loss prediction using digital satellitee data and USLE. In: S Murai (ed). Applications of Remote Sensing in Asia and Oceania – Environmental Change Monitoring. Asian Association of Remote Sensing, pp. 369-372.Salehi MH, Eghbal MK and Khademi H. 2003. Comparison of soil variability in a detailed and a reconnaissance soil map in central Iran. Geoderma 111: 45-56.Soil Survey Staff. 1998. Keys to Soil Taxonomy. Eighth Edition. United States Department of Agriculture Natural Resources Conservation Service. Washington, D.C.